TY - JOUR T1 - A prospective evaluation of the analytical performance of GENECUBE<sup>®</sup> HQ SARS-CoV-2 and GENECUBE<sup>®</sup> FLU A/B JF - medRxiv DO - 10.1101/2021.02.24.21252337 SP - 2021.02.24.21252337 AU - Yoshihiko Kiyasu AU - Yusaku Akashi AU - Akio Sugiyama AU - Yuto Takeuchi AU - Shigeyuki Notake AU - Asami Naito AU - Koji Nakamura AU - Hiroichi Ishikawa AU - Hiromichi Suzuki Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/25/2021.02.24.21252337.abstract N2 - Background Molecular tests are the mainstay for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, their accessibility can be limited by the long examination time and inability to evaluate multiple samples at once. This study evaluated the analytical performance of the newly developed rapid molecular assays GENECUBE® HQ SARS-CoV-2 and the GENECUBE® FLU A/B.Method This prospective study was conducted between December 14, 2020, and January 9, 2021, at a polymerase chain reaction (PCR) center. Samples were collected from the nasopharynx with flocked swabs. Molecular tests were performed with the GENECUBE® system and reference reverse transcription (RT)-PCR, and the results of the two assays were compared.Result Among 1065 samples, 81 (7.6%) were positive for SARS-CoV-2 on the reference RT-PCR. Three showed discordance between GENECUBE® HQ SARS-CoV-2 and the reference RT-PCR; the total, positive and negative samples of concordance for the two assays were 99.7%, 100%, and 99.7%, respectively. All discordant cases were positive for GENECUBE® HQ SARS-CoV-2 and negative for the reference RT-PCR. SARS-CoV-2 was detected from all three samples by another molecular assay for SARS-CoV-2. For the GENECUBE® FLU A/B, the total, positive and negative samples of concordance for the two assays were 99.5%, 100%, and 99.1%.Conclusion The GENECUBE® HQ SARS-CoV-2 and GENECUBE® FLU A/B demonstrated sufficient analytical performance to detect SARS-CoV-2 and influenza virus A/B.Key points We prospectively evaluated the analytical performance of the newly developed rapid molecular assays GENECUBE® HQ SARS-CoV-2 and the GENECUBE® FLU A/B. The two assays showed &gt;99% concordance rate compared with a reference PCR, which indicated their sufficient analytical performance to detect SARS-CoV-2 and influenza virus A/B.Competing Interest StatementTOYOBO Co., Ltd., provided support in the form of salaries to author A. Sugiyama, lecture fees to author H. Suzuki, and advisory fees to author H. Suzuki. The funder did not have any additional role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.Funding StatementThis study was financially supported by TOYOBO Co., Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study was performed in line with the principles of the Declaration of Helsinki and with the guidelines of STROBE. The ethics committee of TMCH approved this study (approval number: 2020-046).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are not publicly available due to their containing information that could compromise the privacy of research participants. ER -